BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank100
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$351.30M
↑ 837% vs avg
Percentile
P100
Near historical high
Streak
3 yr
Consecutive growthExpanding
Average
$-47.67M
Historical baseline
PeriodValueYoY Change
TTM$351.30M+2642.8%
2024$12.81M+111.0%
2023$-116.33M+19.1%
2022$-143.85M-18.2%
2021$-121.74M+27.3%
2020$-167.56M-74.0%
2019$-96.28M-6.5%
2018$-90.36M-59.9%
2017$-56.51M-17.3%
2016$-48.17M-